Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > NanoInk announces the controlled deposition of hydrogels for applied bioscience & biotechnology research

Hydrogel precursors are deposited using DPN followed by a crosslinking step.
Hydrogel precursors are deposited using DPN followed by a crosslinking step.

Abstract:
NanoInk, leaders in nanofabrication applications and instrumentation, announce a new and significant application with excellent potential in biomedical engineering.

NanoInk announces the controlled deposition of hydrogels for applied bioscience & biotechnology research

Skokie, IL | Posted on December 9th, 2009

Using surface topography and chemistry to manipulate cells and tissue in a predictable manner is long term goal of biomaterials researchers. Unfortunately, biological systems are inherently complex and making surfaces with the necessary micro and nanoscale features can be expensive and time consuming. Being able to perform rapid prototyping experiments on length scales of less than two microns opens new opportunities for researchers. The deposition of biocompatible polymers onto a range of substrates offers the ability to understand the binding between cells and surfaces as well as exploring how arbitrary patterns affect cell morphology and behavior. While this is in the early stages of development, the potential for applications in tissue engineering, scaffolds, protein arrays, and neuroscience make this a significant breakthrough.

Using NanoInk's unique patented process of Dip Pen Nanolithography® (DPN®), biocompatible polymers function as simple DPN "inks" enabling one to directly deposit nanoscale features of the polymer, either pure or mixed with some molecule, dye, protein, or peptide. Then, after deposition and depending on the specific polymer, there is a crosslinking step that can be induced by UV, pH or simply heating, transforming the deposited polymer into a nanoscale three dimensional hydrogel network.

There are unique applications in cell motility studies as it is now possible to pattern multiple hydrogels, each with a different cell binding protein or peptide, all in a single parallel experiment. The process can be controlled such that the chemical binding of the hydrogel is altered while retaining its size. This alone will help cut down on the unknowns in biomaterials engineering experiments and finally give researchers the ability to answer many long standing questions about scaffold/substrate and scaffold/cell binding. This opens the way to rapid prototyping of different hydrogel combinations without changing the overall DPN deposition characteristics.

This is a ready-to-use application since no extensive ink development is required. The researcher just has to add the appropriate biomolecule to the hydrogel precursor and commence deposition. As the deposition characteristics are determined by the gel, not the encapsulated biomolecules, the possibilities for this new application of DPN are huge.

Visit NanoInk's web site and read more about the application of DPN and hydrogel inks: www.nanoink.net/ApplicationDevelopment.htm.

####

About NanoInk
NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create nanoscale structures from a wide variety of materials. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop.

Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 140 patents and applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign.

NanoInk, the NanoInk logo, Dip Pen Nanolithography and DPN are trademarks or registered trademarks of NanoInk, Inc.

For more information, please click here

Contacts:
NanoInk, Inc.
8025 Lamon Avenue
Skokie
Illinois 60077
United States of America
T +1 847 745 3619
F +1 847 679 8767


NetDyaLog Limited
39 de Bohun Court
Saffron Walden
Essex CB10 2BA
United Kingdom
T +44(0)1799 521881
F +44(0)1799 521881
www.netdyalog.com


Copyright © NanoInk

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024

Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Possible Futures

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

Nanobiotechnology

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project